Orient Bio

Orient Bio Earnings Yield

The Earnings Yield of Orient Bio (002630.KS) as of Oct 21, 2026 is -7.08 %. In the previous year, Earnings Yield was -20.46 % — a change of -65.39% (higher).

Earnings Yield

-7.08 %

YoY

-65.39%

Last updated:

Earnings Yield of Orient Bio is 2026 -7.08 % . Earnings Yield of Orient Bio was 2025 -20.46 % . It decreases by -65.39% higher compared to the previous year.

The Orient Bio Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2019
-30.24 KRW
Jan 1, 2020
-16.87 KRW
Jan 1, 2021
-23.68 KRW
Jan 1, 2022
53.02 KRW
Jan 1, 2023
-19.26 KRW
Jan 1, 2024
19.95 KRW
Jan 1, 2025
-20.46 KRW
Jan 1, 2026
-7.08 KRW
The Orient Bio Earnings Yield history
YEAREarnings YieldYoY
-7.08 %-65.39%
-20.46 %-202.52%
19.95 %-203.60%
-19.26 %-136.33%
53.02 %-323.88%
-23.68 %+40.39%
-16.87 %-44.22%
-30.24 %+40.68%
-21.50 %-27.51%
-29.65 %+535.59%
-4.67 %+72.04%
-2.71 %-81.69%
-14.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Earnings Yield of Orient Bio is -7.08 % in 2026.

Earnings Yield of Orient Bio changed from -20.46 % to -7.08 %, representing a -65.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Orient Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Orient Bio

All Key Metrics — Orient Bio